New antifungal drug shows promise against deadly fungal infections
NCT ID NCT05630976
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested the safety and effectiveness of the antifungal drug isavuconazole as a first treatment for Chinese patients with serious invasive fungal infections caused by Aspergillus or other molds. All 70 participants received the drug for up to 84 days (or 180 days for certain infections). The main goal was to track side effects, while secondary goals included survival rates. The study is already completed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Isavuconazole (also known as Cresemba), an antifungal drug
What this could lead to
If successful, this study could confirm that isavuconazole is a safe and effective first-line treatment for invasive fungal infections in Chinese patients.
What could go wrong
This is a single-arm, open-label study with no comparison group, so results may be less definitive. The small sample size (70 patients) and specific population may limit how well the findings apply to other groups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INVASIVE FUNGAL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guangzhou First People's Hospital
Guangzhou, Guangdong, 510180, China
-
Henan provincial people's hospital
Zhengzhou, Henan, 450003, China
-
Huashan Hospital, Fudan University
Shanghai, Shanghai Municipality, 200040, China
-
Institute of Hematology, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, 300020, China
-
Jiading Central Hospital
Shanghai, 201800, China
-
Jieyang People's Hospital
Jieyang, Guangdong, 522095, China
-
Liaocheng people's Hospital
Liaocheng, Shandong, 252000, China
-
Peking University People's Hospital
Beijing, 100044, China
-
The First Affiliated Hospital Zhejiang University
Hangzhou, Zhejiang, 310003, China
-
The First Affiliated Hospital of Bengbu Medical College
Bengbu, 233000, China
-
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, 510120, China
-
The First Affiliated Hospital of USTC, Anhui Province Hospital
Hefei, Anhui, 230001, China
-
ZhuJiang Hospital of Southern Medical University
Guangzhou, Guangdong, 510280, China
-
Zibo Central Hospital
Zibo, Shandong, 255036, China